1
|
Bordas-Martinez J, Salord N, Vicens-Zygmunt V, Pérez S, Prado E, Calvo M, Blavia R, Bermudo G, Montes-Worboys A, Santos S, Monasterio C, Molina-Molina M. Characterization of Sleep-Disordered Breathing in Idiopathic Pulmonary Fibrosis. Arch Bronconeumol 2023; 59:768-771. [PMID: 37537074 DOI: 10.1016/j.arbres.2023.07.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2023] [Revised: 07/13/2023] [Accepted: 07/15/2023] [Indexed: 08/05/2023]
Affiliation(s)
- Jaume Bordas-Martinez
- Interstitial Lung Disease Unit, Respiratory Department, Bellvitge University Hospital, IDIBELL, CIBERES, University of Barcelona, Hospitalet de Llobregat, Barcelona, Spain; Sleep Unit, Respiratory Department, Bellvitge University Hospital, IDIBELL, University of Barcelona, Hospitalet de Llobregat, Barcelona, Spain
| | - Neus Salord
- Sleep Unit, Respiratory Department, Bellvitge University Hospital, IDIBELL, University of Barcelona, Hospitalet de Llobregat, Barcelona, Spain
| | - Vanesa Vicens-Zygmunt
- Interstitial Lung Disease Unit, Respiratory Department, Bellvitge University Hospital, IDIBELL, CIBERES, University of Barcelona, Hospitalet de Llobregat, Barcelona, Spain
| | - Sandra Pérez
- Sleep Unit, Respiratory Department, Bellvitge University Hospital, IDIBELL, University of Barcelona, Hospitalet de Llobregat, Barcelona, Spain
| | - Eliseo Prado
- Sleep Unit, Respiratory Department, Bellvitge University Hospital, IDIBELL, University of Barcelona, Hospitalet de Llobregat, Barcelona, Spain
| | - María Calvo
- Sleep Unit, Respiratory Department, Bellvitge University Hospital, IDIBELL, University of Barcelona, Hospitalet de Llobregat, Barcelona, Spain
| | - Rosana Blavia
- Respiratory Department, Hospital Moises Broggi, Sant Joan Despí, Barcelona, Spain
| | - Guadalupe Bermudo
- Interstitial Lung Disease Unit, Respiratory Department, Bellvitge University Hospital, IDIBELL, CIBERES, University of Barcelona, Hospitalet de Llobregat, Barcelona, Spain
| | - Ana Montes-Worboys
- Interstitial Lung Disease Unit, Respiratory Department, Bellvitge University Hospital, IDIBELL, CIBERES, University of Barcelona, Hospitalet de Llobregat, Barcelona, Spain
| | - Salud Santos
- Interstitial Lung Disease Unit, Respiratory Department, Bellvitge University Hospital, IDIBELL, CIBERES, University of Barcelona, Hospitalet de Llobregat, Barcelona, Spain
| | - Carmen Monasterio
- Sleep Unit, Respiratory Department, Bellvitge University Hospital, IDIBELL, University of Barcelona, Hospitalet de Llobregat, Barcelona, Spain.
| | - María Molina-Molina
- Interstitial Lung Disease Unit, Respiratory Department, Bellvitge University Hospital, IDIBELL, CIBERES, University of Barcelona, Hospitalet de Llobregat, Barcelona, Spain
| |
Collapse
|
2
|
Molina-Molina M, Shull JG, Vicens-Zygmunt V, Rivera-Ortega P, Antoniou K, Bonella F, Renzoni E, Russell AM, Maher TM, Vancheri A, Bachs A, Avilés V, Palma J, Bermudo G, Suarez-Cuartin G, Tebé C, Rigo-Bonnin R, Montes-Worboys A, Wijsenbeek M, Vancheri C. Gastrointestinal pirfenidone adverse events in idiopathic pulmonary fibrosis depending on diet: the MADIET clinical trial. Eur Respir J 2023; 62:2300262. [PMID: 37857429 PMCID: PMC10586233 DOI: 10.1183/13993003.00262-2023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2023] [Accepted: 08/18/2023] [Indexed: 10/21/2023]
Abstract
Idiopathic pulmonary fibrosis (IPF) is a chronic and lethal interstitial lung disease (ILD) [1, 2]. Antifibrotic medications such as pirfenidone have been a turning point in the management of IPF, slowing of disease progression and improving survival [1–5]. Individuals with IPF who follow a MUFA diet report a lower incidence of pirfenidone gastrointestinal adverse events than those that follow a SFA diet, which could explain the different prevalence in GI pirfenidone AEs reported by countries in IPF cohorts https://bit.ly/3LuzAUJ
Collapse
Affiliation(s)
- Maria Molina-Molina
- Interstitial Lung Disease Unit, Respiratory Department, University Hospital of Bellvitge, Research Lab 4126, IDIBELL, UB, Barcelona, Spain
- Spanish Research Network in Respiratory Diseases (CIBERES), Barcelona, Spain
| | - Jessica Germaine Shull
- Interstitial Lung Disease Unit, Respiratory Department, University Hospital of Bellvitge, Research Lab 4126, IDIBELL, UB, Barcelona, Spain
| | - Vanesa Vicens-Zygmunt
- Interstitial Lung Disease Unit, Respiratory Department, University Hospital of Bellvitge, Research Lab 4126, IDIBELL, UB, Barcelona, Spain
- Spanish Research Network in Respiratory Diseases (CIBERES), Barcelona, Spain
| | - Pilar Rivera-Ortega
- NIHR Manchester Clinical Research Facility, Interstitial Lung Disease Unit, Respiratory Medicine Department, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, UK
| | - Katerina Antoniou
- Laboratory of Cellular and Molecular Pneumonology, Dept of Respiratory Medicine, School of Medicine, University of Crete, Heraklion, Greece
| | - Francesco Bonella
- Center for Interstitial and Rare Lung Diseases, Ruhrlandklinik, University Hospital, University of Duisburg Essen, Essen, Germany
| | - Elisabetta Renzoni
- NIHR Respiratory Clinical Research Facility, Royal Brompton Hospital, and Fibrosis Research Group, National Heart and Lung Institute, Imperial College, London, UK
| | - Anne-Marie Russell
- Exeter Respiratory Institute, University of Exeter and Royal Devon University Hospitals NHS Foundation Trust, Exeter, UK
| | - Toby M Maher
- Keck Medicine of University of Southern California, Los Angeles, CA, USA
- National Heart and Lung Institute, Imperial College, London, UK
| | - Ada Vancheri
- Dept of Clinical and Experimental Medicine, Regional Referral Centre for Rare Lung Diseases, University Hospital "Policlinico G. Rodolico - San Marco", University of Catania, Catania, Italy
| | - Anna Bachs
- Interstitial Lung Disease Unit, Respiratory Department, University Hospital of Bellvitge, Research Lab 4126, IDIBELL, UB, Barcelona, Spain
| | - Victoria Avilés
- Unit of Nutritional Support, University Hospital of Vall d'Hebron, Barcelona, Spain
| | - Josep Palma
- Interstitial Lung Disease Unit, Respiratory Department, University Hospital of Bellvitge, Research Lab 4126, IDIBELL, UB, Barcelona, Spain
| | - Guadalupe Bermudo
- Interstitial Lung Disease Unit, Respiratory Department, University Hospital of Bellvitge, Research Lab 4126, IDIBELL, UB, Barcelona, Spain
- Spanish Research Network in Respiratory Diseases (CIBERES), Barcelona, Spain
| | - Guillermo Suarez-Cuartin
- Interstitial Lung Disease Unit, Respiratory Department, University Hospital of Bellvitge, Research Lab 4126, IDIBELL, UB, Barcelona, Spain
- Spanish Research Network in Respiratory Diseases (CIBERES), Barcelona, Spain
| | - Cristian Tebé
- Dept of Biostatistics, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain
| | - Raul Rigo-Bonnin
- Dept of Clinical Laboratory, Bellvitge University Hospital, IDIBELL, Barcelona, Spain
| | - Ana Montes-Worboys
- Interstitial Lung Disease Unit, Respiratory Department, University Hospital of Bellvitge, Research Lab 4126, IDIBELL, UB, Barcelona, Spain
- Spanish Research Network in Respiratory Diseases (CIBERES), Barcelona, Spain
| | - Marlies Wijsenbeek
- Dept of Respiratory Medicine, Erasmus University Medical Centre, Rotterdam, The Netherlands
| | - Carlo Vancheri
- Dept of Clinical and Experimental Medicine, Regional Referral Centre for Rare Lung Diseases, University Hospital "Policlinico G. Rodolico - San Marco", University of Catania, Catania, Italy
| |
Collapse
|
3
|
Mercader-Barceló J, Martín-Medina A, Truyols-Vives J, Escarrer-Garau G, Elowsson L, Montes-Worboys A, Río-Bocos C, Muncunill-Farreny J, Velasco-Roca J, Cederberg A, Kadefors M, Molina-Molina M, Westergren-Thorsson G, Sala-Llinàs E. Mitochondrial Dysfunction in Lung Resident Mesenchymal Stem Cells from Idiopathic Pulmonary Fibrosis Patients. Cells 2023; 12:2084. [PMID: 37626894 PMCID: PMC10453747 DOI: 10.3390/cells12162084] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2023] [Revised: 08/09/2023] [Accepted: 08/13/2023] [Indexed: 08/27/2023] Open
Abstract
Idiopathic pulmonary fibrosis (IPF) is characterized by an aberrant repair response with uncontrolled turnover of extracellular matrix involving mesenchymal cell phenotypes, where lung resident mesenchymal stem cells (LRMSC) have been supposed to have an important role. However, the contribution of LRMSC in lung fibrosis is not fully understood, and the role of LRMSC in IPF remains to be elucidated. Here, we performed transcriptomic and functional analyses on LRMSC isolated from IPF and control patients (CON). Both over-representation and gene set enrichment analyses indicated that oxidative phosphorylation is the major dysregulated pathway in IPF LRMSC. The most relevant differences in biological processes included complement activation, mesenchyme development, and aerobic electron transport chain. Compared to CON LRMSC, IPF cells displayed impaired mitochondrial respiration, lower expression of genes involved in mitochondrial dynamics, and dysmorphic mitochondria. These changes were linked to an impaired autophagic response and a lower mRNA expression of pro-apoptotic genes. In addition, IPF TGFβ-exposed LRMSC presented different expression profiles of mitochondrial-related genes compared to CON TGFβ-treated cells, suggesting that TGFβ reinforces mitochondrial dysfunction. In conclusion, these results suggest that mitochondrial dysfunction is a major event in LRMSC and that their occurrence might limit LRMSC function, thereby contributing to IPF development.
Collapse
Affiliation(s)
- Josep Mercader-Barceló
- iRESPIRE Research Group, Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma, Spain
- MolONE Research Group, University of the Balearic Islands, 07122 Palma, Spain
| | - Aina Martín-Medina
- iRESPIRE Research Group, Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma, Spain
| | - Joan Truyols-Vives
- MolONE Research Group, University of the Balearic Islands, 07122 Palma, Spain
| | | | - Linda Elowsson
- Lung Biology, Department of Experimental Medical Science, Lund University, 08908 Lund, Sweden
| | - Ana Montes-Worboys
- ILD Unit, Respiratory Department, University Hospital of Bellvitge-Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, 08908 Barcelona, Spain
| | - Carlos Río-Bocos
- iRESPIRE Research Group, Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma, Spain
| | | | - Julio Velasco-Roca
- Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma, Spain
| | - Anna Cederberg
- Lung Biology, Department of Experimental Medical Science, Lund University, 08908 Lund, Sweden
| | - Måns Kadefors
- Lung Biology, Department of Experimental Medical Science, Lund University, 08908 Lund, Sweden
| | - Maria Molina-Molina
- ILD Unit, Respiratory Department, University Hospital of Bellvitge-Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, 08908 Barcelona, Spain
- Centre of Biomedical Research Network in Respiratory Diseases (CIBERES), 28029 Madrid, Spain
| | | | - Ernest Sala-Llinàs
- iRESPIRE Research Group, Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma, Spain
- Centre of Biomedical Research Network in Respiratory Diseases (CIBERES), 28029 Madrid, Spain
- Respiratory Department, Son Espases University Hospital, 07120 Palma, Spain
| |
Collapse
|
4
|
Ortega FG, Rio C, Jahn A, Gayá A, Calvo J, Monjo M, Montes-Worboys A, Molina-Molina M, Sala-Llinas E, Ramis JM. Antifibrotic Effects of Extracellular Vesicles From Umbilical Cord-Mesenchymal Stem Cells on Lung Myofibroblast Cells. Arch Bronconeumol 2023:S0300-2896(23)00020-0. [PMID: 36822880 DOI: 10.1016/j.arbres.2023.01.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2022] [Revised: 01/06/2023] [Accepted: 01/30/2023] [Indexed: 02/07/2023]
Affiliation(s)
- Francisco G Ortega
- Health Research Institute of the Balearic Islands (IdISBa), Palma, Spain; Cell Therapy and Tissue Engineering Group, Research Institute on Health Sciences (IUNICS), Ctra. Valldemossa km 7.5, 07122 Palma, Spain; IBS Granada, Instituto de Investigación Biosanitaria de Granada, 18012 Granada, Spain; Unidad de Gestión Clínica Cartuja, Distrito Sanitario Granada-Metropolitano, 18013 Granada, Spain
| | - Carlos Rio
- Health Research Institute of the Balearic Islands (IdISBa), Palma, Spain
| | - Andreas Jahn
- Health Research Institute of the Balearic Islands (IdISBa), Palma, Spain
| | - Antonio Gayá
- Health Research Institute of the Balearic Islands (IdISBa), Palma, Spain; Fundació Banc de Sang i Teixits de les Illes Balears (FBSTIB), 07004 Palma, Spain
| | - Javier Calvo
- Health Research Institute of the Balearic Islands (IdISBa), Palma, Spain; Fundació Banc de Sang i Teixits de les Illes Balears (FBSTIB), 07004 Palma, Spain
| | - Marta Monjo
- Health Research Institute of the Balearic Islands (IdISBa), Palma, Spain; Cell Therapy and Tissue Engineering Group, Research Institute on Health Sciences (IUNICS), Ctra. Valldemossa km 7.5, 07122 Palma, Spain; Department of Fundamental Biology and Health Sciences, University of the Balearic Islands (UIB), Ctra. Valldemossa km 7.5, 07122 Palma, Spain.
| | - Ana Montes-Worboys
- ILD Unit, Respiratory Department, University Hospital of Bellvitge, Pneumology Research Group, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain; Centro de Investigación en Red de Enfermedades Respiratorias (CIBERES), 28029 Madrid, Spain
| | - Maria Molina-Molina
- ILD Unit, Respiratory Department, University Hospital of Bellvitge, Pneumology Research Group, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain; Centro de Investigación en Red de Enfermedades Respiratorias (CIBERES), 28029 Madrid, Spain
| | - Ernest Sala-Llinas
- Health Research Institute of the Balearic Islands (IdISBa), Palma, Spain; ILD Unit, Respiratory Department, University Hospital of Bellvitge, Pneumology Research Group, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain; Centro de Investigación en Red de Enfermedades Respiratorias (CIBERES), 28029 Madrid, Spain; Respiratory Department, Hospital Universitari Son Espases, 07010 Palma de Mallorca, Spain
| | - Joana M Ramis
- Health Research Institute of the Balearic Islands (IdISBa), Palma, Spain; Cell Therapy and Tissue Engineering Group, Research Institute on Health Sciences (IUNICS), Ctra. Valldemossa km 7.5, 07122 Palma, Spain; Department of Fundamental Biology and Health Sciences, University of the Balearic Islands (UIB), Ctra. Valldemossa km 7.5, 07122 Palma, Spain.
| |
Collapse
|
5
|
Machahua C, Vicens-Zygmunt V, Ríos-Martín J, Llatjós R, Escobar-Campuzano I, Molina-Molina M, Montes-Worboys A. Collagen 3D matrices as a model for the study of cell behavior in pulmonary fibrosis. Exp Lung Res 2022; 48:126-136. [PMID: 35594338 DOI: 10.1080/01902148.2022.2067265] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Purpose: Idiopathic pulmonary fibrosis (IPF) is a complex progressive chronic lung disease where epithelial to mesenchymal interaction, extracellular matrix (ECM) contact, and pro-fibrotic cytokines dynamics take part in the development of the disease. The study of IPF in the widespread in vitro two-dimensional (2 D) culture fails to explain the interaction of cells with the changing environment that occurs in fibrotic lung tissue. A three-dimensional (3 D) co-culture model might shed light on the pathogenesis of IPF by mimicking the fibrotic environment. Materials and Methods: Fibroblasts from nine IPF were isolated and embedded in collagen matrices with the alveolar epithelial human cell line (A549) on the top. Cells were also cultured in 2 D with and without TGF-β1 as a conventional model to compare with. Both types of cells were isolated separately. Protein and gene expression of the main fibrotic markers were measured by qPCR, Western blot, and ELISA. Results: IPF fibroblasts to myofibroblasts differentiation was observed in the 3 D model and in cells stimulated with TGF-β1. In addition, ECM-related genes were highly up-regulated in the 3 D collagen matrix. A549 co-cultured 3 D with IPF fibroblasts showed EMT activation, with down-regulation of E-cadherin (CDH1). However, other pro-fibrotic genes as VIM, TGFB1, and MMP7 were up-regulated in A549 co-cultured 3 D with fibroblasts. Conclusions: 3 D-collagen matrices might induce fibroblasts' fibrotic phenotype as in the classic TGF-β1 model, by up-regulating genes associated with matrix production. In addition, IPF lung fibroblasts seem to exert a pro-fibrotic influence in A549 cells when they are co-cultured. These results suggest that an improved 3 D co-culture model might serve as an important tool to study the fibrotic process and its regulation.
Collapse
Affiliation(s)
- Carlos Machahua
- Department of Pulmonary Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.,Department for BioMedical Research DBMR, Department of Pulmonary Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.,National Consortium of Research in Respiratory Diseases, CIBERES Instituto de Salud Carlos III, Madrid, Spain
| | - Vanesa Vicens-Zygmunt
- National Consortium of Research in Respiratory Diseases, CIBERES Instituto de Salud Carlos III, Madrid, Spain.,Unit of Interstitial Lung Diseases, Respiratory Department, Bellvitge University Hospital, Respiratory Research group, IDIBELL, Barcelona, Spain
| | - Jesús Ríos-Martín
- Unit of Interstitial Lung Diseases, Respiratory Department, Bellvitge University Hospital, Respiratory Research group, IDIBELL, Barcelona, Spain
| | - Roger Llatjós
- Pathology Department, Bellvitge University Hospital, Barcelona, Spain
| | | | - María Molina-Molina
- National Consortium of Research in Respiratory Diseases, CIBERES Instituto de Salud Carlos III, Madrid, Spain.,Unit of Interstitial Lung Diseases, Respiratory Department, Bellvitge University Hospital, Respiratory Research group, IDIBELL, Barcelona, Spain
| | - Ana Montes-Worboys
- National Consortium of Research in Respiratory Diseases, CIBERES Instituto de Salud Carlos III, Madrid, Spain.,Unit of Interstitial Lung Diseases, Respiratory Department, Bellvitge University Hospital, Respiratory Research group, IDIBELL, Barcelona, Spain
| |
Collapse
|
6
|
Planas-Cerezales L, Arias-Salgado EG, Berastegui C, Montes-Worboys A, González-Montelongo R, Lorenzo-Salazar JM, Vicens-Zygmunt V, Garcia-Moyano M, Dorca J, Flores C, Perona R, Román A, Molina-Molina M. Lung Transplant Improves Survival and Quality of Life Regardless of Telomere Dysfunction. Front Med (Lausanne) 2021; 8:695919. [PMID: 34395476 PMCID: PMC8362799 DOI: 10.3389/fmed.2021.695919] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2021] [Accepted: 05/27/2021] [Indexed: 12/30/2022] Open
Abstract
Introduction: Fibrotic interstitial lung diseases (ILDs) are the first indication for lung transplantation (LT). Telomere dysfunction has been associated with poor post-transplant outcomes. The aim of the study was to evaluate the morbi-mortality and quality of life in fibrotic ILDs after lung transplant depending on telomere biology. Methods: Fibrotic ILD patients that underwent lung transplant were allocated to two arms; with or without telomere dysfunction at diagnosis based on the telomere length and telomerase related gene mutations revealed by whole-exome sequencing. Post-transplant evaluation included: (1) short and long-term mortality and complications and (2) quality of life. Results: Fifty-five percent of patients that underwent LT carried rare coding mutations in telomerase-related genes. Patients with telomere shortening more frequently needed extracorporeal circulation and presented a higher rate of early post-transplant hematological complications, longer stay in the intensive care unit (ICU), and a higher number of long-term hospital admissions. However, post-transplant 1-year survival was higher than 80% regardless of telomere dysfunction, with improvement in the quality of life and oxygen therapy withdrawal. Conclusions: Post-transplant morbidity is higher in patients with telomere dysfunction and differs according to elapsed time from transplantation. However, lung transplant improves survival and quality of life and the associated complications are manageable.
Collapse
Affiliation(s)
- Lurdes Planas-Cerezales
- ILD Multidisciplinary Unit, Hospital Universitari Bellvitge, IDIBELL, Universitat de Barcelona, Hospitalet de Llobregat, Spain
| | - Elena G Arias-Salgado
- Biomedical Research Institute CSIC/UAM, IdIPAZ, Madrid, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Raras, Instituto de Salud Carlos III, Madrid, Spain
| | - Cristina Berastegui
- Respiratory Department, Institute of Research, Hospital Universitari Vall d'Hebrón, Universitat Autónoma de Barcelona, Barcelona, Spain
| | - Ana Montes-Worboys
- ILD Multidisciplinary Unit, Hospital Universitari Bellvitge, IDIBELL, Universitat de Barcelona, Hospitalet de Llobregat, Spain
| | | | - José M Lorenzo-Salazar
- Genomics Division, Instituto Tecnológico y de Energías Renovables, Santa Cruz de Tenerife, Spain
| | - Vanesa Vicens-Zygmunt
- ILD Multidisciplinary Unit, Hospital Universitari Bellvitge, IDIBELL, Universitat de Barcelona, Hospitalet de Llobregat, Spain
| | | | - Jordi Dorca
- ILD Multidisciplinary Unit, Hospital Universitari Bellvitge, IDIBELL, Universitat de Barcelona, Hospitalet de Llobregat, Spain
| | - Carlos Flores
- Genomics Division, Instituto Tecnológico y de Energías Renovables, Santa Cruz de Tenerife, Spain.,Research Unit, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain.,Instituto de Tecnologías Biomédicas, Universidad de La Laguna, Santa Cruz de Tenerife, Spain.,Centro Investigación Biomédica en Red de Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain
| | - Rosario Perona
- Biomedical Research Institute CSIC/UAM, IdIPAZ, Madrid, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Raras, Instituto de Salud Carlos III, Madrid, Spain
| | - Antonio Román
- Respiratory Department, Institute of Research, Hospital Universitari Vall d'Hebrón, Universitat Autónoma de Barcelona, Barcelona, Spain
| | - María Molina-Molina
- ILD Multidisciplinary Unit, Hospital Universitari Bellvitge, IDIBELL, Universitat de Barcelona, Hospitalet de Llobregat, Spain.,Centro Investigación Biomédica en Red de Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain
| |
Collapse
|
7
|
Pintado-Berninches L, Montes-Worboys A, Manguan-García C, Arias-Salgado EG, Serrano A, Fernandez-Varas B, Guerrero-López R, Iarriccio L, Planas L, Guenechea G, Egusquiaguirre SP, Hernandez RM, Igartua M, Luis Pedraz J, Cortijo J, Sastre L, Molina-Molina M, Perona R. GSE4-loaded nanoparticles a potential therapy for lung fibrosis that enhances pneumocyte growth, reduces apoptosis and DNA damage. FASEB J 2021; 35:e21422. [PMID: 33638895 DOI: 10.1096/fj.202001160rr] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2020] [Revised: 01/07/2021] [Accepted: 01/08/2021] [Indexed: 12/13/2022]
Abstract
Idiopathic pulmonary fibrosis is a lethal lung fibrotic disease, associated with aging with a mean survival of 2-5 years and no curative treatment. The GSE4 peptide is able to rescue cells from senescence, DNA and oxidative damage, inflammation, and induces telomerase activity. Here, we investigated the protective effect of GSE4 expression in vitro in rat alveolar epithelial cells (AECs), and in vivo in a bleomycin model of lung fibrosis. Bleomycin-injured rat AECs, expressing GSE4 or treated with GSE4-PLGA/PEI nanoparticles showed an increase of telomerase activity, decreased DNA damage, and decreased expression of IL6 and cleaved-caspase 3. In addition, these cells showed an inhibition in expression of fibrotic markers induced by TGF-β such as collagen-I and III among others. Furthermore, treatment with GSE4-PLGA/PEI nanoparticles in a rat model of bleomycin-induced fibrosis, increased telomerase activity and decreased DNA damage in proSP-C cells. Both in preventive and therapeutic protocols GSE4-PLGA/PEI nanoparticles prevented and attenuated lung damage monitored by SPECT-CT and inhibited collagen deposition. Lungs of rats treated with bleomycin and GSE4-PLGA/PEI nanoparticles showed reduced expression of α-SMA and pro-inflammatory cytokines, increased number of pro-SPC-multicellular structures and increased DNA synthesis in proSP-C cells, indicating therapeutic efficacy of GSE4-nanoparticles in experimental lung fibrosis and a possible curative treatment for lung fibrotic patients.
Collapse
Affiliation(s)
- Laura Pintado-Berninches
- Instituto de Investigaciones Biomédicas, CSIC/UAM, IDIPaz, Madrid, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain
| | - Ana Montes-Worboys
- ILD Unit, Pneumology Department, University Hospital of Bellvitge, IDIBELL, University of Barcelona, Hospitalet de Llobregat, Barcelona, Spain
| | - Cristina Manguan-García
- Instituto de Investigaciones Biomédicas, CSIC/UAM, IDIPaz, Madrid, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain
| | | | - Adela Serrano
- Department of Pharmacology, Faculty of Medicine, University of Valencia, Valencia, Spain.,CIBER of Respiratory diseases (CIBERES), Health Institute Carlos III, Madrid, Spain
| | | | - Rosa Guerrero-López
- Instituto de Investigaciones Biomédicas, CSIC/UAM, IDIPaz, Madrid, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain
| | - Laura Iarriccio
- Instituto de Investigaciones Biomédicas, CSIC/UAM, IDIPaz, Madrid, Spain
| | - Lurdes Planas
- ILD Unit, Pneumology Department, University Hospital of Bellvitge, IDIBELL, University of Barcelona, Hospitalet de Llobregat, Barcelona, Spain
| | - Guillermo Guenechea
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain.,Division of Hematopoietic Innovative Therapies, Centro de Investigaciones Energéticas Medioambientales y Tecnológicas (CIEMAT), Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD/UAM), Madrid, Spain
| | - Susana P Egusquiaguirre
- NanoBioCel Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country (UPV/EHU), CIBER-BBN, Vitoria-Gasteiz, Spain
| | - Rosa M Hernandez
- NanoBioCel Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country (UPV/EHU), CIBER-BBN, Vitoria-Gasteiz, Spain
| | - Manoli Igartua
- NanoBioCel Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country (UPV/EHU), CIBER-BBN, Vitoria-Gasteiz, Spain
| | - Jose Luis Pedraz
- NanoBioCel Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country (UPV/EHU), CIBER-BBN, Vitoria-Gasteiz, Spain
| | - Julio Cortijo
- Department of Pharmacology, Faculty of Medicine, University of Valencia, Valencia, Spain.,CIBER of Respiratory diseases (CIBERES), Health Institute Carlos III, Madrid, Spain
| | - Leandro Sastre
- Instituto de Investigaciones Biomédicas, CSIC/UAM, IDIPaz, Madrid, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain
| | - Maria Molina-Molina
- ILD Unit, Pneumology Department, University Hospital of Bellvitge, IDIBELL, University of Barcelona, Hospitalet de Llobregat, Barcelona, Spain.,CIBER of Respiratory diseases (CIBERES), Health Institute Carlos III, Madrid, Spain
| | - Rosario Perona
- Instituto de Investigaciones Biomédicas, CSIC/UAM, IDIPaz, Madrid, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain
| |
Collapse
|
8
|
Merino A, Hoogduijn MJ, Molina-Molina M, Arias-Salgado EG, Korevaar SS, Baan CC, Montes-Worboys A. Membrane particles from mesenchymal stromal cells reduce the expression of fibrotic markers on pulmonary cells. PLoS One 2021; 16:e0248415. [PMID: 33730089 PMCID: PMC7968667 DOI: 10.1371/journal.pone.0248415] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2020] [Accepted: 02/26/2021] [Indexed: 11/18/2022] Open
Abstract
BACKGROUND Idiopathic pulmonary fibrosis (IPF) is a devastating lung disease with limited treatment options in which the telomere shortening is a strong predictive factor of poor prognosis. Mesenchymal stromal cells (MSC) administration is probed in several experimental induced lung pathologies; however, MSC might stimulate fibrotic processes. A therapy that avoids MSC side effects of transformation would be an alternative to the use of living cells. Membranes particles (MP) are nanovesicles artificially generated from the membranes of MSC containing active enzymes involved in ECM regeneration. We aimed to investigate the anti-fibrotic role of MP derived from MSC in an in vitro model of pulmonary fibrosis. METHODS Epithelial cells (A549) and lung fibroblasts, from IPF patients with different telomere length, were co-cultured with MP and TGF-β for 48h and gene expression of major pro-fibrotic markers were analyzed. RESULTS About 90% of both types of cells effectively took up MP without cytotoxic effects. MP decreased the expression of profibrotic proteins such as Col1A1, Fibronectin and PAI-1, in A549 cells. In fibroblasts culture, there was a different response in the inhibitory effect of MP on some pro-fibrotic markers when comparing fibroblast from normal telomere length patients (FN) versus short telomere length (FS), but both types showed an inhibition of Col1A1, Tenascin-c, PAI-1 and MMP-1 gene expression after MP treatment. CONCLUSIONS MP conserve some of the properties attributed to the living MSC. This study shows that MP target lung cells, via which they may have a broad anti-fibrotic effect.
Collapse
Affiliation(s)
- Ana Merino
- Department of Internal Medicine, Nephrology and Transplantation, Erasmus Medical Center, Rotterdam, The Netherlands
| | - Martin J. Hoogduijn
- Department of Internal Medicine, Nephrology and Transplantation, Erasmus Medical Center, Rotterdam, The Netherlands
| | - Maria Molina-Molina
- Unit of Interstitial Lung Diseases, Pulmonary Department, University Hospital of Bellvitge, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain
- CIBER of Respiratory Diseases (CIBERES) Health Institute Carlos III, Madrid, Spain
| | | | - Sander S. Korevaar
- Department of Internal Medicine, Nephrology and Transplantation, Erasmus Medical Center, Rotterdam, The Netherlands
| | - Carla C. Baan
- Department of Internal Medicine, Nephrology and Transplantation, Erasmus Medical Center, Rotterdam, The Netherlands
| | - Ana Montes-Worboys
- Unit of Interstitial Lung Diseases, Pulmonary Department, University Hospital of Bellvitge, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain
| |
Collapse
|
9
|
Machahua C, Guler SA, Horn MP, Planas-Cerezales L, Montes-Worboys A, Geiser TK, Molina-Molina M, Funke-Chambour M. Serum calprotectin as new biomarker for disease severity in idiopathic pulmonary fibrosis: a cross-sectional study in two independent cohorts. BMJ Open Respir Res 2021; 8:8/1/e000827. [PMID: 33451989 PMCID: PMC7813379 DOI: 10.1136/bmjresp-2020-000827] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2020] [Revised: 12/11/2020] [Accepted: 12/13/2020] [Indexed: 12/16/2022] Open
Abstract
BACKGROUND Non-invasive biomarkers for the assessment of disease severity in idiopathic pulmonary fibrosis (IPF) are urgently needed. Calprotectin belongs to the S-100 proteins produced by neutrophils, which likely contribute to IPF pathogenesis. Calprotectin is a well-established biomarker in inflammatory bowel diseases. In this cross-sectional study, we aimed to establish the potential role of calprotectin as a biomarker in IPF. Specifically, we hypothesised that patients with IPF have higher serum calprotectin levels compared with healthy controls, and that calprotectin levels are associated with disease severity. METHODS Blood samples were obtained from healthy volunteers (n=26) and from two independent IPF cohorts (derivation cohort n=26, validation cohort n=66). Serum calprotectin levels were measured with a commercial kit adapted for that purpose and compared between healthy controls and patients with IPF. Clinical parameters, including forced vital capacity, diffusing capacity for carbon monoxide (DLCO) and the Composite Physiologic Index (CPI), were correlated with calprotectin serum levels. RESULTS The IPF derivation cohort showed increased serum calprotectin levels compared with healthy controls (2.47±1.67 vs 0.97±0.53 µg/mL, p<0.001). In addition, serum calprotectin levels correlated with DLCO% predicted (r=-0.53, p=0.007) and with CPI (r=0.66, p=0.007). These findings were confirmed in an independent IPF validation cohort. CONCLUSION Serum calprotectin levels are significantly increased in patients with IPF compared with healthy controls and correlate with DLCO and CPI. Calprotectin might be a potential new biomarker for disease severity in IPF.
Collapse
Affiliation(s)
- Carlos Machahua
- Department for Pulmonary Medicine, Inselspital, Bern University Hospital, Department for BioMedical Research (DBMR), University of Bern, Bern, Switzerland.,Department of Pulmonary Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
| | - Sabina A Guler
- Department for Pulmonary Medicine, Inselspital, Bern University Hospital, Department for BioMedical Research (DBMR), University of Bern, Bern, Switzerland.,Department of Pulmonary Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
| | - Michael P Horn
- Department of Clinical Chemistry, Inselspital University Hospital Bern, Bern, Switzerland
| | - Lurdes Planas-Cerezales
- Unit of interstitial lung disease, Department of Pneumology, University Hospital of Bellvitge L'Hospitalet de Llobregat, Barcelona, Spain.,Pneumology Research Group, Institut D'Investigació Biomedica de Bellvitge IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain
| | - Ana Montes-Worboys
- Pneumology Research Group, Institut D'Investigació Biomedica de Bellvitge IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain
| | - Thomas K Geiser
- Department for Pulmonary Medicine, Inselspital, Bern University Hospital, Department for BioMedical Research (DBMR), University of Bern, Bern, Switzerland.,Department of Pulmonary Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
| | - Maria Molina-Molina
- Unit of interstitial lung disease, Department of Pneumology, University Hospital of Bellvitge L'Hospitalet de Llobregat, Barcelona, Spain.,Pneumology Research Group, Institut D'Investigació Biomedica de Bellvitge IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain
| | - Manuela Funke-Chambour
- Department for Pulmonary Medicine, Inselspital, Bern University Hospital, Department for BioMedical Research (DBMR), University of Bern, Bern, Switzerland .,Department of Pulmonary Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
| |
Collapse
|
10
|
Calero C, López-Campos JL, Gómez Izquierdo L, Sánchez-Silva R, López-Villalobos JL, Sáenz-Coronilla FJ, Arellano-Orden E, Montes-Worboys A, Echevarría M. Expression of aquaporins in bronchial tissue and lung parenchyma of patients with chronic obstructive pulmonary disease. Multidiscip Respir Med 2019. [DOI: 10.4081/mrm.2014.405] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Background: Aquaporins AQP1 and AQP5 are highly expressed in the lung. Recent studies have shown that the expression of these proteins may be mechanistically involved in the airway inflammation and in the pathogenesis of chronic obstructive pulmonary disease (COPD). The aim of this study was to investigate the expression of AQP1 and AQP5 in the bronchial tissue and the lung parenchyma of patients with COPD and COPD-resistant smokers.
Methods: Using a case–control design, we selected a group of 15 subjects with COPD and 15 resistant smokers (smokers without COPD) as a control, all of whom were undergoing lung resection surgery due to a lung neoplasm. We studied the expression of AQP1 and AQP5 in the bronchial tissue and the lung parenchyma by means of immunohistochemistry and reverse-transcription real-time polymerase chain reaction. Tissue expression of AQP1 and AQP5 was semi-quantitatively assessed in terms of intensity and expression by immunohistochemistry using a 4-point scale ranging from 0 (none) to 3 (maximum).
Results: There were no significant differences in gene expression between COPD patients and resistant smokers both in the bronchial tissue and in the lung parenchyma. However, AQP1 gene expression was 2.41-fold higher in the parenchyma of smokers with COPD compared to controls, whereas the AQP5 gene showed the opposite pattern, with a 7.75-fold higher expression in the bronchus of smokers with COPD compared with controls. AQP1 and AQP5 proteins were preferentially expressed in endothelial cells, showing a higher intensity for AQP1 (66.7% of cases with an intensity of 3, and 93.3% of subjects with an extension of 3 among patients with COPD). Subtle interstitial disease was associated with type II pneumocyte hyperplasia and an increased expression of AQP1.
Conclusions: This study provides pilot observations on the differences in AQP1 and AQP5 expression between COPD patients and COPD-resistant smokers. Our findings suggest a potential role for AQP1 in the pathogenesis of COPD.
Collapse
|
11
|
Machahua C, Montes-Worboys A, Planas-Cerezales L, Buendia-Flores R, Molina-Molina M, Vicens-Zygmunt V. Serum AGE/RAGEs as potential biomarker in idiopathic pulmonary fibrosis. Respir Res 2018; 19:215. [PMID: 30409203 PMCID: PMC6225674 DOI: 10.1186/s12931-018-0924-7] [Citation(s) in RCA: 34] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2018] [Accepted: 10/28/2018] [Indexed: 12/16/2022] Open
Abstract
Background The soluble receptor for advanced glycation end-products (sRAGE) has been suggested that it acts as a decoy for capturing advanced glycation end-products (AGEs) and inhibits the activation of the oxidative stress and apoptotic pathways. Lung AGEs/sRAGE is increased in idiopathic pulmonary fibrosis (IPF). The objective of the study was to evaluate the AGEs and sRAGE levels in serum as a potential biomarker in IPF. Methods Serum samples were collected from adult patients: 62 IPF, 22 chronic hypersensitivity pneumonitis (cHP), 20 fibrotic non-specific interstitial pneumonia (fNSIP); and 12 healthy controls. In addition, 23 IPF patients were re-evaluated after 3-year follow-up period. Epidemiological and clinical features were recorded: age, sex, smoking habits, and lung function. AGEs and sRAGE were evaluated by ELISA, and the results were correlated with pulmonary functional test values. Results IPF and cHP groups presented a significant increase of AGE/sRAGE serum concentration compared with fNSIP patients. Moreover, an inverse correlation between AGEs and sRAGE levels were found in IPF, and serum sRAGE at diagnosis correlated with FVC and DLCO values. Additionally, changes in serum AGEs and sRAGE correlated with % change of FVC, DLCO and TLC during the follow-up. sRAGE levels below 428.25 pg/ml evolved poor survival rates. Conclusions These findings demonstrate that the increase of AGE/sRAGE ratio is higher in IPF, although the levels were close to cHP. AGE/sRAGE increase correlates with respiratory functional progression. Furthermore, the concentration of sRAGE in blood stream at diagnosis and follow-up could be considered as a potential prognostic biomarker. Electronic supplementary material The online version of this article (10.1186/s12931-018-0924-7) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Carlos Machahua
- Pneumology Research Group, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.,Biomedical Research Network Centers in Respiratory Diseases (CIBERES), Barcelona, Spain
| | - Ana Montes-Worboys
- Pneumology Research Group, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.,Biomedical Research Network Centers in Respiratory Diseases (CIBERES), Barcelona, Spain.,Unit of Interstitial Lung Diseases, Department of Pneumology, University Hospital of Bellvitge, C. Feixa Llarga sn., 08907 L'Hospitalet de Llobregat, Barcelona, Spain
| | - Lurdes Planas-Cerezales
- Pneumology Research Group, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.,Unit of Interstitial Lung Diseases, Department of Pneumology, University Hospital of Bellvitge, C. Feixa Llarga sn., 08907 L'Hospitalet de Llobregat, Barcelona, Spain
| | | | - Maria Molina-Molina
- Pneumology Research Group, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain. .,Biomedical Research Network Centers in Respiratory Diseases (CIBERES), Barcelona, Spain. .,Unit of Interstitial Lung Diseases, Department of Pneumology, University Hospital of Bellvitge, C. Feixa Llarga sn., 08907 L'Hospitalet de Llobregat, Barcelona, Spain.
| | - Vanesa Vicens-Zygmunt
- Pneumology Research Group, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.,Unit of Interstitial Lung Diseases, Department of Pneumology, University Hospital of Bellvitge, C. Feixa Llarga sn., 08907 L'Hospitalet de Llobregat, Barcelona, Spain
| |
Collapse
|
12
|
Planas-Cerezales L, Arias-Salgado EG, Buendia-Roldán I, Montes-Worboys A, López CE, Vicens-Zygmunt V, Hernaiz PL, Sanuy RL, Leiro-Fernandez V, Vilarnau EB, Llinás ES, Sargatal JD, Abellón RP, Selman M, Molina-Molina M. Predictive factors and prognostic effect of telomere shortening in pulmonary fibrosis. Respirology 2018; 24:146-153. [PMID: 30320420 DOI: 10.1111/resp.13423] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2017] [Revised: 09/11/2018] [Accepted: 09/12/2018] [Indexed: 01/04/2023]
Abstract
BACKGROUND AND OBJECTIVE The abnormal shortening of telomeres is a mechanism linking ageing to idiopathic pulmonary fibrosis (IPF) that could be useful in the clinical setting. The objective of this study was to identify the IPF patients with higher risk for telomere shortening and to investigate the outcome implications. METHODS Consecutive Spanish patients were included at diagnosis and followed up for 3 years. DNA blood samples from a Mexican cohort were used to validate the results found in Spanish sporadic IPF. Prior to treatment, telomere length was measured through quantitative polymerase chain reaction (qPCR) and Southern blot. Outcome was assessed according to mortality or need for lung transplantation. A multivariate regression logistic model was used for statistical analysis. RESULTS Family aggregation, age of <60 years and the presence of non-specific immunological or haematological abnormalities were associated with a higher probability of telomere shortening. Overall, 66.6% of patients younger than 60 years with telomere shortening died or required lung transplantation, independent of functional impairment at diagnosis. By contrast, in patients older than 60 years with telomere shortening, the negative impact of telomere shortening in outcome was not significant. CONCLUSION Our data indicate that young sporadic IPF patients (<60 years) with some non-specific immunological or haematological abnormalities had higher risk of telomere shortening, and furthermore, they presented a poorer prognosis.
Collapse
Affiliation(s)
- Lurdes Planas-Cerezales
- Centro de Investigación en Red de Enfermedades Respiratorias (CIBERES), Madrid, Spain.,Unidad Funcional de Intersticio Pulmonar, Servicio Neumología, Hospital Universitario de Bellvitge, Instituto de Investigación Biomédica de Bellvitge (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain
| | - Elena G Arias-Salgado
- Advanced Medical Projects, Madrid, Spain.,Instituto de Investigaciones Biomédicas, Consejo Superior de Investigaciones Científicas (CSIC)/Universidad Autónoma de Madrid (UAM), Centro de Investigación en Red de Enfermedades Raras (CIBERER), Madrid, Spain
| | - Ivette Buendia-Roldán
- Instituto Nacional de Enfermedades Respiratorias, "Ismael Cosío Villegas", México City, Mexico
| | - Ana Montes-Worboys
- Centro de Investigación en Red de Enfermedades Respiratorias (CIBERES), Madrid, Spain.,Unidad Funcional de Intersticio Pulmonar, Servicio Neumología, Hospital Universitario de Bellvitge, Instituto de Investigación Biomédica de Bellvitge (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain
| | - Cristina Esquinas López
- Centro de Investigación en Red de Enfermedades Respiratorias (CIBERES), Madrid, Spain.,Servicio de Neumología, Hospital Vall d'Hebron, Barcelona, Spain
| | - Vanesa Vicens-Zygmunt
- Unidad Funcional de Intersticio Pulmonar, Servicio Neumología, Hospital Universitario de Bellvitge, Instituto de Investigación Biomédica de Bellvitge (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain
| | - Patricio Luburich Hernaiz
- Unidad Funcional de Intersticio Pulmonar. Servicio Radiodiagnóstico, Hospital Universitario de Bellvitge, Instituto de Investigación Biomédica de Bellvitge (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain
| | - Roger Llatjós Sanuy
- Unidad Funcional de Intersticio Pulmonar, Servicio de Anatomía Patológica, Hospital Universitario de Bellvitge, Instituto de Investigación Biomédica de Bellvitge (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain
| | - Virginia Leiro-Fernandez
- Servicio de Neumología, Complexo Hospitalario Universitario de Vigo (CHUVI), Vigo, Spain.,Grupo de Investigación en Respiratorio, Instituto de Investigación Biomédica de Vigo, Vigo, Spain
| | - Eva Balcells Vilarnau
- Centro de Investigación en Red de Enfermedades Respiratorias (CIBERES), Madrid, Spain.,Servicio de Neumología, Hospital del Mar, Instituto Hospital del Mar de Investigaciones Médicas (IMIM), Universidad Pompeu Fabra (UPF), Barcelona, Spain
| | - Ernest Sala Llinás
- Centro de Investigación en Red de Enfermedades Respiratorias (CIBERES), Madrid, Spain.,Servicio de Neumología, Hospital Son Espases, Instituto de Investigación Sanitaria Islas Baleares (IdISBa), Palma de Mallorca, Spain
| | - Jordi Dorca Sargatal
- Centro de Investigación en Red de Enfermedades Respiratorias (CIBERES), Madrid, Spain.,Unidad Funcional de Intersticio Pulmonar, Servicio Neumología, Hospital Universitario de Bellvitge, Instituto de Investigación Biomédica de Bellvitge (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain
| | - Rosario Perona Abellón
- Instituto de Investigaciones Biomédicas, Consejo Superior de Investigaciones Científicas (CSIC)/Universidad Autónoma de Madrid (UAM), Centro de Investigación en Red de Enfermedades Raras (CIBERER), Madrid, Spain
| | - Moisés Selman
- Instituto Nacional de Enfermedades Respiratorias, "Ismael Cosío Villegas", México City, Mexico
| | - Maria Molina-Molina
- Centro de Investigación en Red de Enfermedades Respiratorias (CIBERES), Madrid, Spain.,Unidad Funcional de Intersticio Pulmonar, Servicio Neumología, Hospital Universitario de Bellvitge, Instituto de Investigación Biomédica de Bellvitge (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain
| |
Collapse
|
13
|
Molina-Molina M, Machahua-Huamani C, Vicens-Zygmunt V, Llatjós R, Escobar I, Sala-Llinas E, Luburich-Hernaiz P, Dorca J, Montes-Worboys A. Anti-fibrotic effects of pirfenidone and rapamycin in primary IPF fibroblasts and human alveolar epithelial cells. BMC Pulm Med 2018; 18:63. [PMID: 29703175 PMCID: PMC5922028 DOI: 10.1186/s12890-018-0626-4] [Citation(s) in RCA: 51] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2017] [Accepted: 04/16/2018] [Indexed: 01/23/2023] Open
Abstract
BACKGROUND Pirfenidone, a pleiotropic anti-fibrotic treatment, has been shown to slow down disease progression of idiopathic pulmonary fibrosis (IPF), a fatal and devastating lung disease. Rapamycin, an inhibitor of fibroblast proliferation could be a potential anti-fibrotic drug to improve the effects of pirfenidone. METHODS Primary lung fibroblasts from IPF patients and human alveolar epithelial cells (A549) were treated in vitro with pirfenidone and rapamycin in the presence or absence of transforming growth factor β1 (TGF-β). Extracellular matrix protein and gene expression of markers involved in lung fibrosis (tenascin-c, fibronectin, collagen I [COL1A1], collagen III [COL3A1] and α-smooth muscle actin [α-SMA]) were analyzed. A cell migration assay in pirfenidone, rapamycin and TGF-β-containing media was performed. RESULTS Gene and protein expression of tenascin-c and fibronectin of fibrotic fibroblasts were reduced by pirfenidone or rapamycin treatment. Pirfenidone-rapamycin treatment did not revert the epithelial to mesenchymal transition pathway activated by TGF-β. However, the drug combination significantly abrogated fibroblast to myofibroblast transition. The inhibitory effect of pirfenidone on fibroblast migration in the scratch-wound assay was potentiated by rapamycin combination. CONCLUSIONS These findings indicate that the combination of pirfenidone and rapamycin widen the inhibition range of fibrogenic markers and prevents fibroblast migration. These results would open a new line of research for an anti-fibrotic combination therapeutic approach.
Collapse
Affiliation(s)
- M. Molina-Molina
- Department of Pneumology, Bellvitge University Hospital, Barcelona, Spain
- Pneumology Research Group, IDIBELL, University of Barcelona, Barcelona, Spain
- Research Network in Respiratory Diseases (CIBERES), ISCIII, Madrid, Spain
| | - C. Machahua-Huamani
- Pneumology Research Group, IDIBELL, University of Barcelona, Barcelona, Spain
| | - V. Vicens-Zygmunt
- Department of Pneumology, Bellvitge University Hospital, Barcelona, Spain
- Pneumology Research Group, IDIBELL, University of Barcelona, Barcelona, Spain
| | - R. Llatjós
- Department of Pathology, Bellvitge University Hospital, Barcelona, Spain
| | - I. Escobar
- Department of Thoracic Surgery, Bellvitge University Hospital, Barcelona, Spain
| | - E. Sala-Llinas
- Research Network in Respiratory Diseases (CIBERES), ISCIII, Madrid, Spain
- Department of Penumology, Son Espases University Hospital, Palma de Mallorca, Spain
| | - P. Luburich-Hernaiz
- Servei de Diagnostic per la Imatge El Prat (SDPI El Prat) Department of Radiology, Bellvitge University Hospital, Barcelona, Spain
| | - J. Dorca
- Department of Pneumology, Bellvitge University Hospital, Barcelona, Spain
- Pneumology Research Group, IDIBELL, University of Barcelona, Barcelona, Spain
- Research Network in Respiratory Diseases (CIBERES), ISCIII, Madrid, Spain
| | - A. Montes-Worboys
- Department of Pneumology, Bellvitge University Hospital, Barcelona, Spain
- Pneumology Research Group, IDIBELL, University of Barcelona, Barcelona, Spain
- Research Network in Respiratory Diseases (CIBERES), ISCIII, Madrid, Spain
- Laboratori de Pneumologia Experimental (Lab. 4126). IDIBELL, Pavelló de Govern. Campus de Bellvitge, Universitat de Barcelona, Hospital de Bellvitge, Carrer de la Feixa Llarga, 08907 L’Hospitalet de Llobregat, Barcelona, Spain
| |
Collapse
|
14
|
Arellano-Orden E, Serrano C, Montes-Worboys A, Sánchez-López V, Laborda A, Lostalé F, Lahuerta C, Rodríguez-Panadero F, de Gregorio MÁ. Stent-induced tracheal stenosis can be predicted by IL-8 expression in rabbits. Eur J Clin Invest 2017; 47:84-92. [PMID: 27873304 DOI: 10.1111/eci.12706] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/26/2016] [Accepted: 11/18/2016] [Indexed: 12/27/2022]
Abstract
BACKGROUND Bare metal stents may cause complications like fibrous encapsulation, granulation and tracheal stenosis. We investigated the behaviour of three commercially available stents in vivo (rabbits) and in vitro (coculture of those stents with epithelial and fibroblast cell lines). Also, we investigated whether development of tracheal stenosis could be predicted by any biological marker. MATERIALS AND METHODS The tracheae of 30 rabbits were implanted with either nitinol stents, with or without paclitaxel elution, or a cobalt-based stent. An additional ten rabbits underwent mock implantation (controls). Serial peripheral venous blood samples were taken throughout the study, and several cytokines measured. Animals were euthanized on day 90, with immediate tracheal endoscopy and lavage performed, then necropsy. RESULTS Rabbits with cobalt-based stent exhibited more inflammation and the highest stenosis incidence, with reduced survival. Both in vivo and in vitro, this stent induced higher IL-8 levels than nitinol stents. Most important, the presence of stent-induced tracheal stenosis was closely associated to increase in IL-8 expression in blood just 1 day after tracheal stent implantation: a 1·19-fold increase vs. baseline had 83% sensitivity, 83% specificity, 77% positive predictive value, 88% negative predictive value and 83% accuracy to predict development of stenosis. CONCLUSIONS The cobalt-based stent had the highest incidence of tracheal inflammation and stenosis. On the other hand, the paclitaxel-eluting nitinol stent did not prevent those complications and provoked a marked reaction compared with the bare nitinol stent. Early increase in IL-8 expression in blood after stent implantation could predict development of tracheal stenosis in rabbits.
Collapse
Affiliation(s)
- Elena Arellano-Orden
- Unidad Médico-Quirúrgica de Enfermedades Respiratorias, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/Universidad de Sevilla, Seville, Spain
| | - Carolina Serrano
- Minimally Invasive Techniques Research Group (GITMI), University of Zaragoza, Zaragoza, Spain
| | - Ana Montes-Worboys
- Unidad Médico-Quirúrgica de Enfermedades Respiratorias, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/Universidad de Sevilla, Seville, Spain
| | - Verónica Sánchez-López
- Unidad Médico-Quirúrgica de Enfermedades Respiratorias, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/Universidad de Sevilla, Seville, Spain
| | - Alicia Laborda
- Minimally Invasive Techniques Research Group (GITMI), University of Zaragoza, Zaragoza, Spain
| | - Fernando Lostalé
- Minimally Invasive Techniques Research Group (GITMI), University of Zaragoza, Zaragoza, Spain
| | - Celia Lahuerta
- Minimally Invasive Techniques Research Group (GITMI), University of Zaragoza, Zaragoza, Spain
| | - Francisco Rodríguez-Panadero
- Unidad Médico-Quirúrgica de Enfermedades Respiratorias, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/Universidad de Sevilla, Seville, Spain.,CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
| | - Miguel Ángel de Gregorio
- Minimally Invasive Techniques Research Group (GITMI), University of Zaragoza, Zaragoza, Spain.,Interventional Radiology, Hospital Clinico Universitario, University of Zaragoza, Zaragoza, Spain.,CIBER Bioengineering, Biomaterials and Nanomedicine (BBB), Instituto de Salud Carlos III, Madrid, Spain
| |
Collapse
|
15
|
Machahua C, Montes-Worboys A, Llatjos R, Escobar I, Dorca J, Molina-Molina M, Vicens-Zygmunt V. Increased AGE-RAGE ratio in idiopathic pulmonary fibrosis. Respir Res 2016; 17:144. [PMID: 27816054 PMCID: PMC5097848 DOI: 10.1186/s12931-016-0460-2] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2016] [Accepted: 10/28/2016] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND The abnormal epithelial-mesenchymal restorative capacity in idiopathic pulmonary fibrosis (IPF) has been recently associated with an accelerated aging process as a key point for the altered wound healing. The advanced glycation end-products (AGEs) are the consequence of non-enzymatic reactions between lipid and protein with several oxidants in the aging process. The receptor for AGEs (RAGEs) has been implicated in the lung fibrotic process and the alveolar homeostasis. However, this AGE-RAGE aging pathway has been under-explored in IPF. METHODS Lung samples from 16 IPF and 9 control patients were obtained through surgical lung biopsy. Differences in AGEs and RAGE expression between both groups were evaluated by RT-PCR, Western blot and immunohistochemistry. The effect of AGEs on cell viability of primary lung fibrotic fibroblasts and alveolar epithelial cells was assessed. Cell transformation of fibrotic fibroblasts cultured into glycated matrices was evaluated in different experimental conditions. RESULTS Our study demonstrates an increase of AGEs together with a decrease of RAGEs in IPF lungs, compared with control samples. Two specific AGEs involved in aging, pentosidine and Nε-Carboxymethyl lysine, were significantly increased in IPF samples. The immunohistochemistry identified higher staining of AGEs related to extracellular matrix (ECM) proteins and the apical surface of the alveolar epithelial cells (AECs) surrounding fibroblast foci in fibrotic lungs. On the other hand, RAGE location was present at the cell membrane of AECs in control lungs, while it was almost missing in pulmonary fibrotic tissue. In addition, in vitro cultures showed that the effect of AGEs on cell viability was different for AECs and fibrotic fibroblasts. AGEs decreased cell viability in AECs, even at low concentration, while fibroblast viability was less affected. Furthermore, fibroblast to myofibroblast transformation could be enhanced by ECM glycation. CONCLUSIONS All of these findings suggest a possible role of the increased ratio AGEs-RAGEs in IPF, which could be a relevant accelerating aging tissue reaction in the abnormal wound healing of the lung fibrotic process.
Collapse
Affiliation(s)
- Carlos Machahua
- Pneumology Research Group, IDIBELL, University of Barcelona, Barcelona, Spain
- Department of Pneumology, Unit of Interstitial Lung Diseases, University Hospital of Bellvitge, Barcelona, Spain
| | - Ana Montes-Worboys
- Pneumology Research Group, IDIBELL, University of Barcelona, Barcelona, Spain
- Department of Pneumology, Unit of Interstitial Lung Diseases, University Hospital of Bellvitge, Barcelona, Spain
- Research Network in Respiratory Diseases (CIBERES), Madrid, Spain
| | - Roger Llatjos
- Department of Pathology, University Hospital of Bellvitge, Barcelona, Spain
| | - Ignacio Escobar
- Department of Thoracic Surgery, University Hospital of Bellvitge, Barcelona, Spain
| | - Jordi Dorca
- Pneumology Research Group, IDIBELL, University of Barcelona, Barcelona, Spain
- Department of Pneumology, Unit of Interstitial Lung Diseases, University Hospital of Bellvitge, Barcelona, Spain
- Research Network in Respiratory Diseases (CIBERES), Madrid, Spain
| | - Maria Molina-Molina
- Pneumology Research Group, IDIBELL, University of Barcelona, Barcelona, Spain
- Department of Pneumology, Unit of Interstitial Lung Diseases, University Hospital of Bellvitge, Barcelona, Spain
- Research Network in Respiratory Diseases (CIBERES), Madrid, Spain
| | - Vanesa Vicens-Zygmunt
- Pneumology Research Group, IDIBELL, University of Barcelona, Barcelona, Spain
- Department of Pneumology, Unit of Interstitial Lung Diseases, University Hospital of Bellvitge, Barcelona, Spain
| |
Collapse
|
16
|
Vicens-Zygmunt V, Estany S, Colom A, Montes-Worboys A, Machahua C, Sanabria AJ, Llatjos R, Escobar I, Manresa F, Dorca J, Navajas D, Alcaraz J, Molina-Molina M. Erratum to: Fibroblast viability and phenotypic changes within glycated stiffened three-dimensional collagen matrices. Respir Res 2015; 16:136. [PMID: 26525898 PMCID: PMC4630872 DOI: 10.1186/s12931-015-0277-4] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2015] [Accepted: 09/24/2015] [Indexed: 11/10/2022] Open
Affiliation(s)
- Vanesa Vicens-Zygmunt
- Department of Pneumology, Unit of Interstitial Lung Diseases, University Hospital of Bellvitge, Barcelona, Spain. .,Pneumology Research Group, IDIBELL, University of Barcelona, Barcelona, Spain.
| | - Susanna Estany
- Pneumology Research Group, IDIBELL, University of Barcelona, Barcelona, Spain
| | - Adai Colom
- Unit of Biophysics and Bioengineering, University of Barcelona, Barcelona, Spain.,Department of Biochemistry, University of Geneva, Science II, Geneva, Switzerland
| | - Ana Montes-Worboys
- Pneumology Research Group, IDIBELL, University of Barcelona, Barcelona, Spain
| | - Carlos Machahua
- Pneumology Research Group, IDIBELL, University of Barcelona, Barcelona, Spain
| | | | - Roger Llatjos
- Pneumology Research Group, IDIBELL, University of Barcelona, Barcelona, Spain.,Department of Pathology, University Hospital of Bellvitge, Barcelona, Spain
| | - Ignacio Escobar
- Department of Thoracic Surgery, University Hospital of Bellvitge, Barcelona, Spain
| | - Frederic Manresa
- Department of Pneumology, Unit of Interstitial Lung Diseases, University Hospital of Bellvitge, Barcelona, Spain.,Pneumology Research Group, IDIBELL, University of Barcelona, Barcelona, Spain
| | - Jordi Dorca
- Department of Pneumology, Unit of Interstitial Lung Diseases, University Hospital of Bellvitge, Barcelona, Spain.,Pneumology Research Group, IDIBELL, University of Barcelona, Barcelona, Spain
| | - Daniel Navajas
- Unit of Biophysics and Bioengineering, University of Barcelona, Barcelona, Spain.,Research Network in Respiratory Diseases (Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Respiratorias), ISCIII, Barcelona, Spain
| | - Jordi Alcaraz
- Unit of Biophysics and Bioengineering, University of Barcelona, Barcelona, Spain.,Research Network in Respiratory Diseases (Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Respiratorias), ISCIII, Barcelona, Spain
| | - Maria Molina-Molina
- Department of Pneumology, Unit of Interstitial Lung Diseases, University Hospital of Bellvitge, Barcelona, Spain.,Pneumology Research Group, IDIBELL, University of Barcelona, Barcelona, Spain.,Research Network in Respiratory Diseases (Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Respiratorias), ISCIII, Barcelona, Spain
| |
Collapse
|
17
|
Vicens-Zygmunt V, Estany S, Colom A, Montes-Worboys A, Machahua C, Sanabria AJ, Llatjos R, Escobar I, Manresa F, Dorca J, Navajas D, Alcaraz J, Molina-Molina M. Fibroblast viability and phenotypic changes within glycated stiffened three-dimensional collagen matrices. Respir Res 2015; 16:82. [PMID: 26126411 PMCID: PMC4494165 DOI: 10.1186/s12931-015-0237-z] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2015] [Accepted: 06/10/2015] [Indexed: 12/04/2022] Open
Abstract
Background There is growing interest in the development of cell culture assays that enable the rigidity of the extracellular matrix to be increased. A promising approach is based on three-dimensional collagen type I matrices that are stiffened by cross-linking through non-enzymatic glycation with reducing sugars. Methods The present study evaluated the biomechanical changes in the non-enzymatically glycated type I collagen matrices, including collagen organization, the advanced glycation end products formation and stiffness achievement. Gels were glycated with ribose at different concentrations (0, 5, 15, 30 and 240 mM). The viability and the phenotypic changes of primary human lung fibroblasts cultured within the non-enzymatically glycated gels were also evaluated along three consecutive weeks. Statistical tests used for data analyze were Mann–Whitney U, Kruskal Wallis, Student’s t-test, two-way ANOVA, multivariate ANOVA, linear regression test and mixed linear model. Results Our findings indicated that the process of collagen glycation increases the stiffness of the matrices and generates advanced glycation end products in a ribose concentration-dependent manner. Furthermore, we identified optimal ribose concentrations and media conditions for cell viability and growth within the glycated matrices. The microenvironment of this collagen based three-dimensional culture induces α-smooth muscle actin and tenascin-C fibroblast protein expression. Finally, a progressive contractile phenotype cell differentiation was associated with the contraction of these gels. Conclusions The use of non-enzymatic glycation with a low ribose concentration may provide a suitable model with a mechanic and oxidative modified environment with cells embedded in it, which allowed cell proliferation and induced fibroblast phenotypic changes. Such culture model could be appropriate for investigations of the behavior and phenotypic changes in cells that occur during lung fibrosis as well as for testing different antifibrotic therapies in vitro. Electronic supplementary material The online version of this article (doi:10.1186/s12931-015-0237-z) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Vanesa Vicens-Zygmunt
- Department of Pneumology, Unit of Interstitial Lung Diseases, University Hospital of Bellvitge, Barcelona, Spain. .,Pneumology Research Group, IDIBELL, University of Barcelona, Barcelona, Spain.
| | - Susanna Estany
- Pneumology Research Group, IDIBELL, University of Barcelona, Barcelona, Spain.
| | - Adai Colom
- Unit of Biophysics and Bioengineering, University of Barcelona, Barcelona, Spain. .,Department of Biochemistry, University of Geneva, Science II, Geneva, Switzerland.
| | - Ana Montes-Worboys
- Pneumology Research Group, IDIBELL, University of Barcelona, Barcelona, Spain.
| | - Carlos Machahua
- Pneumology Research Group, IDIBELL, University of Barcelona, Barcelona, Spain.
| | | | - Roger Llatjos
- Pneumology Research Group, IDIBELL, University of Barcelona, Barcelona, Spain. .,Department of Pathology, University Hospital of Bellvitge, Barcelona, Spain.
| | - Ignacio Escobar
- Department of Thoracic Surgery, University Hospital of Bellvitge, Barcelona, Spain.
| | - Frederic Manresa
- Department of Pneumology, Unit of Interstitial Lung Diseases, University Hospital of Bellvitge, Barcelona, Spain. .,Pneumology Research Group, IDIBELL, University of Barcelona, Barcelona, Spain.
| | - Jordi Dorca
- Department of Pneumology, Unit of Interstitial Lung Diseases, University Hospital of Bellvitge, Barcelona, Spain. .,Pneumology Research Group, IDIBELL, University of Barcelona, Barcelona, Spain.
| | - Daniel Navajas
- Unit of Biophysics and Bioengineering, University of Barcelona, Barcelona, Spain. .,Research Network in Respiratory Diseases (Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Respiratorias), ISCIII, Barcelona, Spain.
| | - Jordi Alcaraz
- Unit of Biophysics and Bioengineering, University of Barcelona, Barcelona, Spain. .,Research Network in Respiratory Diseases (Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Respiratorias), ISCIII, Barcelona, Spain.
| | - Maria Molina-Molina
- Department of Pneumology, Unit of Interstitial Lung Diseases, University Hospital of Bellvitge, Barcelona, Spain. .,Pneumology Research Group, IDIBELL, University of Barcelona, Barcelona, Spain. .,Research Network in Respiratory Diseases (Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Respiratorias), ISCIII, Barcelona, Spain.
| |
Collapse
|
18
|
Calero C, López-Campos JL, Izquierdo LG, Sánchez-Silva R, López-Villalobos JL, Sáenz-Coronilla FJ, Arellano-Orden E, Montes-Worboys A, Echevarría M. Expression of aquaporins in bronchial tissue and lung parenchyma of patients with chronic obstructive pulmonary disease. Multidiscip Respir Med 2014; 9:29. [PMID: 24917931 PMCID: PMC4050095 DOI: 10.1186/2049-6958-9-29] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2014] [Accepted: 04/29/2014] [Indexed: 11/10/2022] Open
Abstract
Background Aquaporins AQP1 and AQP5 are highly expressed in the lung. Recent studies have shown that the expression of these proteins may be mechanistically involved in the airway inflammation and in the pathogenesis of chronic obstructive pulmonary disease (COPD). The aim of this study was to investigate the expression of AQP1 and AQP5 in the bronchial tissue and the lung parenchyma of patients with COPD and COPD-resistant smokers. Methods Using a case–control design, we selected a group of 15 subjects with COPD and 15 resistant smokers (smokers without COPD) as a control, all of whom were undergoing lung resection surgery due to a lung neoplasm. We studied the expression of AQP1 and AQP5 in the bronchial tissue and the lung parenchyma by means of immunohistochemistry and reverse-transcription real-time polymerase chain reaction. Tissue expression of AQP1 and AQP5 was semi-quantitatively assessed in terms of intensity and expression by immunohistochemistry using a 4-point scale ranging from 0 (none) to 3 (maximum). Results There were no significant differences in gene expression between COPD patients and resistant smokers both in the bronchial tissue and in the lung parenchyma. However, AQP1 gene expression was 2.41-fold higher in the parenchyma of smokers with COPD compared to controls, whereas the AQP5 gene showed the opposite pattern, with a 7.75-fold higher expression in the bronchus of smokers with COPD compared with controls. AQP1 and AQP5 proteins were preferentially expressed in endothelial cells, showing a higher intensity for AQP1 (66.7% of cases with an intensity of 3, and 93.3% of subjects with an extension of 3 among patients with COPD). Subtle interstitial disease was associated with type II pneumocyte hyperplasia and an increased expression of AQP1. Conclusions This study provides pilot observations on the differences in AQP1 and AQP5 expression between COPD patients and COPD-resistant smokers. Our findings suggest a potential role for AQP1 in the pathogenesis of COPD.
Collapse
Affiliation(s)
- Carmen Calero
- Unidad Médico-Quirúrgica de Enfermedades Respiratorias, Hospital Universitario Virgen del Rocio, Sevilla, Spain ; Instituto de Biomedicina de Sevilla (IBiS), Avda. Manuel Siurot, s/n 41013, Sevilla, Spain ; CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
| | - Jose Luis López-Campos
- Unidad Médico-Quirúrgica de Enfermedades Respiratorias, Hospital Universitario Virgen del Rocio, Sevilla, Spain ; Instituto de Biomedicina de Sevilla (IBiS), Avda. Manuel Siurot, s/n 41013, Sevilla, Spain ; CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
| | - Lourdes Gómez Izquierdo
- Departamento de Anatomía Patológica, Hospital Universitario Virgen del Rocio, Sevilla, Spain
| | - Rocío Sánchez-Silva
- Instituto de Biomedicina de Sevilla (IBiS), Avda. Manuel Siurot, s/n 41013, Sevilla, Spain
| | - Jose Luis López-Villalobos
- Unidad Médico-Quirúrgica de Enfermedades Respiratorias, Hospital Universitario Virgen del Rocio, Sevilla, Spain ; Instituto de Biomedicina de Sevilla (IBiS), Avda. Manuel Siurot, s/n 41013, Sevilla, Spain
| | | | - Elena Arellano-Orden
- Unidad Médico-Quirúrgica de Enfermedades Respiratorias, Hospital Universitario Virgen del Rocio, Sevilla, Spain ; Instituto de Biomedicina de Sevilla (IBiS), Avda. Manuel Siurot, s/n 41013, Sevilla, Spain
| | - Ana Montes-Worboys
- Unidad Médico-Quirúrgica de Enfermedades Respiratorias, Hospital Universitario Virgen del Rocio, Sevilla, Spain ; Instituto de Biomedicina de Sevilla (IBiS), Avda. Manuel Siurot, s/n 41013, Sevilla, Spain ; CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
| | - Miriam Echevarría
- Instituto de Biomedicina de Sevilla (IBiS), Avda. Manuel Siurot, s/n 41013, Sevilla, Spain ; CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
| |
Collapse
|
19
|
Lopez-Campos JL, Calero C, Arellano-Orden E, Marquez-Martín E, Cejudo-Ramos P, Ortega Ruiz F, Montes-Worboys A. Increased levels of soluble ICAM-1 in chronic obstructive pulmonary disease and resistant smokers are related to active smoking. Biomark Med 2013; 6:805-11. [PMID: 23227846 DOI: 10.2217/bmm.12.64] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
AIM Serum ICAM-1 (sICAM-1) is known to be a smoking-associated inflammatory marker, but data in chronic obstructive pulmonary disease (COPD) are lacking. PATIENTS & METHODS A total of 142 COPD cases (48 active smokers) and 55 controls (41 active smokers) were consecutively enrolled in this cross-sectional study. The peripheral blood concentrations of sICAM-1, IL-8 (CXCL8), CRP and serum amyloid A (SAA) were determined by ELISA. RESULTS CRP and SAA (log-scale) were elevated in the patients with COPD compared with the control subjects (p = 0.005 for CRP and p = 0.024 for SAA). sICAM-1 was associated with active smoking when corrected for age, gender, the presence of COPD, inhaled corticosteroid use, BMI and forced expiratory volume in 1 s as covariates. CONCLUSION The present study confirms an association between sICAM-1 levels and active smoking in a group of COPD and non-COPD active smokers.
Collapse
Affiliation(s)
- Jose Luis Lopez-Campos
- Unidad Medico-Quirúrgica de Enfermedades Respiratorias, Instituto de Biomedicina de Sevilla-IBiS, Hospital Universitario Virgen del Rocio, Avda Manual Siurot, s/n, 41013 Seville, Spain.
| | | | | | | | | | | | | |
Collapse
|
20
|
López-Campos JL, Calero C, Rojano B, López-Porras M, Sáenz-Coronilla J, Blanco AI, Sánchez-López V, Tobar D, Montes-Worboys A, Arellano E. C-reactive protein and serum amyloid a overexpression in lung tissues of chronic obstructive pulmonary disease patients: a case-control study. Int J Med Sci 2013; 10:938-47. [PMID: 23801879 PMCID: PMC3691791 DOI: 10.7150/ijms.6152] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/26/2013] [Accepted: 05/13/2013] [Indexed: 12/04/2022] Open
Abstract
BACKGROUND Although researchers have consistently demonstrated systemic inflammation in chronic obstructive pulmonary disease (COPD), its origin is yet unknown. We aimed to compare the lung bronchial and parenchymal tissues as potential sources of major acute-phase reactants in COPD patients and resistant smokers. METHODS Consecutive patients undergoing elective surgery for suspected primary lung cancer were considered for the study. Patients were categorized as COPD or resistant smokers according to their spirometric results. Lung parenchyma and bronchus sections distant from the primary lesion were obtained. C-reactive protein (CRP) and serum amyloid A (SAA1, SAA2 and SAA4) gene expressions were evaluated by RT-PCR. Protein levels were evaluated in paraffin embedded lung tissues by immunohistochemistry and in serum samples by nephelometry. RESULTS Our study included 85 patients with COPD and 87 resistant smokers. In bronchial and parenchymal tissues, both CRP and SAA were overexpressed in COPD patients. In the bronchus, CRP, SAA1, SAA2, and SA4 gene expressions in COPD patients were 1.89-fold, 4.36-fold, 3.65-fold, and 3.9-fold the control values, respectively. In the parenchyma, CRP, SAA1, and SAA2 gene expressions were 2.41-, 1.97-, and 1.76-fold the control values, respectively. Immunohistochemistry showed an over-stained pattern of these markers on endovascular cells of COPD patients. There was no correlation with serum protein concentration. CONCLUSIONS These results indicate an overexpression of CRP and SAA in both bronchial and parenchymal tissue in COPD, which differs between both locations, indicating tissue/cell type specificity. The endothelial cells might play a role in the production of theses markers.
Collapse
Affiliation(s)
- Jose Luis López-Campos
- Unidad Medico-Quirurgica de Enfermedades Respiratorias. Hospital Universitario Virgen del Rocio, Seville, Spain.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Regev D, Surolia R, Karki S, Zolak J, Montes-Worboys A, Oliva O, Guroji P, Saini V, Steyn AJC, Agarwal A, Antony VB. Heme oxygenase-1 promotes granuloma development and protects against dissemination of mycobacteria. J Transl Med 2012; 92:1541-52. [PMID: 22964851 PMCID: PMC4017357 DOI: 10.1038/labinvest.2012.125] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Non-tuberculous mycobacterial (NTM) infections occur in both immunocompromised and immunocompetent hosts and are an increasingly recognized cause of morbidity and mortality. The hallmark of pulmonary mycobacterial infections is the formation of granuloma in the lung. Our study focuses on the role of heme oxygenase-1 (HO-1), a cytoprotective enzyme, in the regulation of granuloma development and maturation following infection with Mycobacterium avium. We examined the role of HO-1 in regulating monocyte chemoattractant protein-1 (MCP-1) and chemokine receptor 2 (CCR2), two molecules involved in monocyte-macrophage cell trafficking after infection. We showed that RAW 264.7 mouse monocytes exposed to M. avium expressed HO-1 and MCP-1. Inhibition of HO by zinc protoporphyrin-IX led to inhibition of MCP-1 and increased expression of CCR2, its cognate receptor. HO-1⁻/⁻ mice did not develop organized granuloma in their lungs, had higher lung colony forming unit of M. avium when infected with intratracheal M. avium, and had loose collections of inflammatory cells in the lung parenchyma. Mycobacteria were found only inside defined granulomas but not outside granuloma in the lungs of HO-1⁺/⁺ mice. In HO-1⁻/⁻ mice, mycobacteria were also found in the liver and spleen and showed increased mortality. Peripheral blood monocytes isolated from GFP⁺ mice and given intravenously to HO-1⁺/⁺ mice localized into tight granulomas, while in HO-1⁻/⁻ mice they remained diffusely scattered in areas of parenchymal inflammation. Higher MCP-1 levels were found in bronchoalveolar lavage fluid of M. avium infected HO-1(-/-) mice and CCR2 expression was higher in HO-1⁻/⁻ alveolar macrophages when compared with HO-1⁺/⁺ mice. CCR2 expression localized to granuloma in HO-1⁺/⁺ mice but not in the HO-1⁻/⁻ mice. These findings strongly suggest that HO-1 plays a protective role in the control of M. avium infection.
Collapse
Affiliation(s)
- Doron Regev
- Division of Pulmonary, Critical Care & Sleep Medicine, College of Medicine, University of Florida, Gainesville, Florida, USA
| | - Ranu Surolia
- Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA
| | - Suman Karki
- Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA
| | - Jason Zolak
- Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA
| | - Ana Montes-Worboys
- Unidad Médico-Quirúrgica de Enfermedades Respiratorias, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío, Sevilla, Spain
| | - Ocatvio Oliva
- Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA
| | - Purushotum Guroji
- Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA
| | - Vikram Saini
- Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama, USA
| | - Adrie JC Steyn
- Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama, USA,KwaZulu-Natal Research Institute for TB and HIV, Durban 4001, South Africa
| | - Anupam Agarwal
- Division of Nephrology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama USA
| | - Veena. B. Antony
- Division of Pulmonary, Critical Care & Sleep Medicine, College of Medicine, University of Florida, Gainesville, Florida, USA,Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA,Corresponding Author: Veena B Antony, MD, Professor of Medicine, University of Alabama at Birmingham, 1530, 3rd Avenue South, THT 422, Birmingham, AL 35294-0006., Tel: (205) 934-0892. Fax: (205) 934-1721,
| |
Collapse
|
22
|
Sánchez-López V, Vila V, Martinez-Salas V, Martín-Rodriguez E, Montes-Worboys A, Arellano E, Elias T, Otero R. C0280 Correlation between annexinV-FITC and Annexin V-V450 positive microparticles in two high sensitivity cytometers. Thromb Res 2012. [DOI: 10.1016/j.thromres.2012.08.216] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
23
|
Arellano-Orden E, Romero-Falcon A, Juan JM, Ocaña Jurado M, Rodriguez-Panadero F, Montes-Worboys A. Small Particle-Size Talc Is Associated with Poor Outcome and Increased Inflammation in Thoracoscopic Pleurodesis. Respiration 2012; 86:201-9. [DOI: 10.1159/000342042] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2012] [Accepted: 07/09/2012] [Indexed: 11/19/2022] Open
|
24
|
López-Campos JL, Arellano E, Calero C, Delgado A, Márquez E, Cejudo P, Ortega F, Rodríguez-Panadero F, Montes-Worboys A. Determination of inflammatory biomarkers in patients with COPD: a comparison of different assays. BMC Med Res Methodol 2012; 12:40. [PMID: 22463705 PMCID: PMC3340310 DOI: 10.1186/1471-2288-12-40] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2011] [Accepted: 03/31/2012] [Indexed: 11/25/2022] Open
Abstract
Background Chronic obstructive pulmonary disease (COPD) is an inflammatory pulmonary disorder with systemic inflammatory manifestations that are mediated by circulating acute-phase reactants. This study compared an enzyme-linked immunosorbent assay (ELISA) to a nephelometric technique for the measurement of serum C-reactive protein (CRP) and serum amyloid A (SAA) and investigated how the choice of assay influenced the estimation of inflammation in patients with stable COPD. Methods CRP and SAA concentrations measured by ELISA and nephelometry in 88 patients with COPD and 45 control subjects were used to evaluate the performance of these methods in a clinical setting. Results With both assays, the concentrations of CRP and SAA were higher in COPD patients than in controls after adjustment for age and sex. There was a moderate correlation between the values measured by ELISA and those measured by nephelometry (logCRP: r = 0.55, p < 0.001; logSAA: r = 0.40, p < 0.001). However, the concentrations of biomarkers determined by nephelometry were significantly higher than those obtained with ELISA for CRP (mean difference = 2.7 (9.4) mg/L) and SAA (mean difference = 0.31 (14.3) mg/L). Conclusion Although the serum CRP and SAA concentrations measured by ELISA and nephelometry correlated well in COPD patients, the ELISA values tended to be lower for CRP and SAA when compared with nephelometric measurements. International standardization of commercial kits is required before the predictive validity of inflammatory markers for patients with COPD can be effectively assessed in clinical practice.
Collapse
Affiliation(s)
- José L López-Campos
- Unidad Médico-Quirúrgica de Enfermedades Respiratorias, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío, Sevilla, Spain.
| | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Abstract
Pleurodesis aims to obliterate the pleural space by producing extensive adhesion of the visceral and parietal pleura, in order to control relapse of either pleural effusions (mostly malignant) or pneumothorax. A tight and complete apposition between the two pleural layers is a necessary condition to obtain a successful pleurodesis, but--besides this mechanical aspect--there are many biological mechanisms that appear to be common to most of the sclerosing agents currently used. Following intrapleural application of the sclerosing agent, diffuse inflammation, pleural coagulation-fibrinolysis imbalance (favoring the formation of fibrin adhesions), recruitment and subsequent proliferation of fibroblasts, and collagen production are findings in the pleural space. The pleural mesothelial lining is the primary target for the sclerosant and plays a pivotal role in the whole pleurodesis process, including the release of several mediators like interleukin-8, transforming growth factor-β and basic fibroblast growth factor. When the tumor burden is high, normal mesothelial cells are scarce, and consequently the response to the sclerosing agent is decreased, leading to failure of pleurodesis. Also, the type of tumor in the pleural cavity may also affect the outcome of pleurodesis (diffuse malignant mesothelioma and metastatic lung carcinomas have a poorer response). There is general agreement that talc obtains the best results, and there are also preliminary experimental studies suggesting that it can induce apoptosis in tumor cells and inhibit angiogenesis, thus contributing to a better control of the malignant pleural effusion. There is concern about complications (possibly associated with talc but other agents as well) related to systemic inflammation and possible activation of the coagulation cascade. In order to prevent extrapleural talc dissemination, large-particle talc is recommended. Although it could--to some degree--interfere with the mechanisms leading to pleurodesis and a carefully balanced clinical decision has therefore to be made, prophylactic treatment with subcutaneous heparin is recommended during hospitalization (immediately before and after the pleurodesis procedure).
Collapse
Affiliation(s)
- Francisco Rodriguez-Panadero
- Unidad Médico-Quirúrgica de Enfermedades Respiratorias, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla, and CIBER Enfermedades Respiratorias, Sevilla, Spain.
| | | |
Collapse
|
26
|
López-Campos JL, Montes-Worboys A, Calero C, Márquez-Martin E, Cejudo P, Ortega F, Arellano E. Cyclooxygenase-2 -765G>C polymorphism is associated with C-reactive protein levels in resistant smokers but not in chronic obstructive pulmonary disease patients. Respir Physiol Neurobiol 2011; 180:119-25. [PMID: 22100366 DOI: 10.1016/j.resp.2011.11.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2011] [Revised: 11/01/2011] [Accepted: 11/03/2011] [Indexed: 11/29/2022]
Abstract
We sought to investigate whether the serum concentrations of several inflammatory biomarkers are related to the cyclooxygenase-2 (COX2) -765G>C polymorphism in chronic obstructive pulmonary disease (COPD) and a control group of non-COPD smokers. Serum inflammatory markers (CRP, SAA, CXCL8, and sICAM-1) were measured by ELISA in 144 patients with COPD and in 55 control subjects. Genomic DNA was extracted from peripheral blood leukocytes, and the COX2 -765G>C (rs20417) polymorphism was genotyped. After adjustment for age and active smoking, CRP and SAA concentrations were associated with the COX2 polymorphism in controls (p=0.041 and 0.014, respectively) but not in COPD patients. The CXCL8 and sICAM-1 concentrations were not associated with the COX2 polymorphism for either cases or controls. The results of the present study indicate that there is a relationship between the COX2 -765G>C polymorphism and the concentrations of CRP and SAA in non-COPD smokers and that this relationship does not exist in COPD patients.
Collapse
Affiliation(s)
- José Luis López-Campos
- Unidad Médico-Quirúrgica de Enfermedades Respiratorias, Hospital Universitario Virgen del Rocío, Sevilla, Spain.
| | | | | | | | | | | | | |
Collapse
|
27
|
|
28
|
Mubarak KK, Montes-Worboys A, Regev D, Nasreen N, Mohammed KA, Faruqi I, Hensel E, Baz MA, Akindipe OA, Fernandez-Bussy S, Nathan SD, Antony VB. Parenchymal trafficking of pleural mesothelial cells in idiopathic pulmonary fibrosis. Eur Respir J 2011; 39:133-40. [DOI: 10.1183/09031936.00141010] [Citation(s) in RCA: 62] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
29
|
Montes-Worboys A, Brown S, Regev D, Bellew BF, Mohammed KA, Faruqi I, Sharma P, Moudgil B, Antony VB. Targeted delivery of amikacin into granuloma. Am J Respir Crit Care Med 2010; 182:1546-53. [PMID: 20693382 PMCID: PMC3029940 DOI: 10.1164/rccm.200912-1888oc] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2009] [Accepted: 08/06/2010] [Indexed: 11/16/2022] Open
Abstract
RATIONALE Nontuberculous mycobacterial (NTM) infection is a growing problem in the United States and remains underrecognized in the developing world. The management of NTM infections is further complicated by several factors, including the need to use high systemic doses of toxic agents, the length of therapy, and the development of drug resistance. OBJECTIVES We have evaluated the use of monocyte-derived dendritic cells (DCs) as a delivery vehicle for a luminescent derivative of amikacin prepared by conjugation to fluorescein isothiocyanate (FITC) (amikacin-FITC) into granulomas formed in the tissues of mice infected with Mycobacterium avium. METHODS Amikacin-FITC was prepared and quantitative fluorescence was used to track the intracellular uptake of this modified antibiotic. The antibiotic activity of amikacin-FITC was also determined to be comparable to unmodified amikacin against M. avium. Amikacin-FITC-loaded DCs were first primed with M. avium, and then the cells were injected into the tail vein of infected mice. After 24 hours, the mice were sacrificed and the tissues were analyzed under fluorescence microscope. MEASUREMENTS AND MAIN RESULTS We found that we were able to deliver amikacin into granulomas in a mouse model of disseminated mycobacterial infection. No increase in levels of monocyte chemoattractant protein-1 and its CCR2 as markers of inflammation were found when DCs were treated with amikacin-FITC. CONCLUSIONS DC-based drug delivery may be an adjunct and useful method of delivering high local concentrations of antibiotics into mycobacterial granulomas.
Collapse
Affiliation(s)
- Ana Montes-Worboys
- Division of Pulmonary Critical Care and Sleep Medicine, College of Medicine, Particle Engineering Research Center, Center for Nano-Bio Sensors, and Malcom Randall Veterans Affairs Medical Center, University of Florida, Gainesville, Florida
| | - Scott Brown
- Division of Pulmonary Critical Care and Sleep Medicine, College of Medicine, Particle Engineering Research Center, Center for Nano-Bio Sensors, and Malcom Randall Veterans Affairs Medical Center, University of Florida, Gainesville, Florida
| | - Doron Regev
- Division of Pulmonary Critical Care and Sleep Medicine, College of Medicine, Particle Engineering Research Center, Center for Nano-Bio Sensors, and Malcom Randall Veterans Affairs Medical Center, University of Florida, Gainesville, Florida
| | - Brendan F. Bellew
- Division of Pulmonary Critical Care and Sleep Medicine, College of Medicine, Particle Engineering Research Center, Center for Nano-Bio Sensors, and Malcom Randall Veterans Affairs Medical Center, University of Florida, Gainesville, Florida
| | - Kamal A. Mohammed
- Division of Pulmonary Critical Care and Sleep Medicine, College of Medicine, Particle Engineering Research Center, Center for Nano-Bio Sensors, and Malcom Randall Veterans Affairs Medical Center, University of Florida, Gainesville, Florida
| | - Ibrahim Faruqi
- Division of Pulmonary Critical Care and Sleep Medicine, College of Medicine, Particle Engineering Research Center, Center for Nano-Bio Sensors, and Malcom Randall Veterans Affairs Medical Center, University of Florida, Gainesville, Florida
| | - Parvesh Sharma
- Division of Pulmonary Critical Care and Sleep Medicine, College of Medicine, Particle Engineering Research Center, Center for Nano-Bio Sensors, and Malcom Randall Veterans Affairs Medical Center, University of Florida, Gainesville, Florida
| | - Brij Moudgil
- Division of Pulmonary Critical Care and Sleep Medicine, College of Medicine, Particle Engineering Research Center, Center for Nano-Bio Sensors, and Malcom Randall Veterans Affairs Medical Center, University of Florida, Gainesville, Florida
| | - Veena B. Antony
- Division of Pulmonary Critical Care and Sleep Medicine, College of Medicine, Particle Engineering Research Center, Center for Nano-Bio Sensors, and Malcom Randall Veterans Affairs Medical Center, University of Florida, Gainesville, Florida
| |
Collapse
|
30
|
López-Campos JL, Rodríguez-Rodríguez D, Rodríguez-Becerra E, Alfageme-Michavila I, Fernández-Guerra J, García-Hernández FJ, Casanova A, Fernández de Córdoba J, Romero-Ortiz A, Arellano-Orden E, Montes-Worboys A. [Cyclooxygenase-2 polymorphisms and bronchoalveolar lavage cellularity of sarcoidosis]. Rev Invest Clin 2010; 62:440-446. [PMID: 21416732] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
OBJECTIVES Recent studies have found cyclooxygenase-2 (COX-2) and its polymorphisms to be associated with sarcoidosis, being it significantly decreased in alveolar macrophages, with no information on the relationship between these polymorphisms and the rest of cells in bronchoalveolar layage (BAL). The present study aimed to investigate the potential association between COX-2 gene polymorphisms and the BAL cell profile including the CD4/CD8 ratio. MATERIAL AND METHODS This observational cross-sectional study involved six hospitals in Spain. Patients diagnosed with sarcoidosis with a BAL performed were included. The following variables were recorded: age, gender, initial diagnostic methods, serum angiotensin-converting enzyme levels, pulmonary function tests, radiological stage, and the cellularity and CD4/CD8 ratio from BAL. Genotyping of four COX-2 polymorphisms (COX2.5909T>G, COX2.8473T>C, COX2.926G>C, and COX2.3050G>C) was undertaken on DNA extracted from peripheral blood lymphocytes using fluorescent hybridization probes. The relationship between the polymorphisms and the cellularity was done by means of a multiple linear regression, adjusting for gender. RESULTS A total of 51 sarcoid patients (23 males, mean age: 45 +/- 15 years) were studied. CD4/CD8 ratio was significantly higher among homozygote allele C carriers of the polymorphism COX2.8473T>C (CC 11.2 +/- 5.5 vs. CT+TT 4.4 +/- 3.5; p = 0.022; beta = 7.43; 95% CI 1.38 - 13.48). Although several differences were observed in other cell groups, they did not reach the statistical significance level. CONCLUSIONS In patients diagnosed with sarcoidosis, there seems to be a relationship between COX2.8473 polymorphism and CD4/CD8 ratio from BAL.
Collapse
Affiliation(s)
- José Luis López-Campos
- Unidad Médico-Quirúirgica de Enfermedades Respiratorias, Hospital Universitario Virgen del Rocío, Sevilla, España.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Montes-Worboys A, Rodriguez-Portal JA, Arellano-Orden E, Digon-Pereiras J, Rodriguez-Panadero F. Interleukin-8 activates coagulation and correlates with survival after talc pleurodesis. Eur Respir J 2009; 35:160-6. [DOI: 10.1183/09031936.00146808] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
32
|
Lopez-Campos JL, Rodriguez-Rodriguez D, Rodriguez-Becerra E, Alfageme Michavila I, Guerra JF, Hernandez FJG, Casanova A, Fernández de Córdoba Gamero J, Romero-Ortiz A, Arellano-Orden E, Montes-Worboys A. Cyclooxygenase-2 polymorphisms confer susceptibility to sarcoidosis but are not related to prognosis. Respir Med 2008; 103:427-33. [PMID: 19042116 DOI: 10.1016/j.rmed.2008.09.014] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/29/2008] [Revised: 08/12/2008] [Accepted: 09/23/2008] [Indexed: 10/21/2022]
Abstract
BACKGROUND The aim of this multicenter study was to investigate the relationship between single nucleotide polymorphisms (SNPs) of the cyclooxygenase-2 (COX2) gene and susceptibility to sarcoidosis, as well as the relation between these SNPs and the evolution of the disease. MATERIAL AND METHODS This multicenter investigation involved seven hospitals in Spain. We used a case-control design followed by a prospective follow-up study. Sarcoid patients were recruited from the participating institutions during outpatient routine visits. Age- and gender-matched control subjects were recruited mainly from among outpatients attending the participating hospitals. Four SNPs in the COX2 gene (COX2.5909 T > G, COX2.8473 T > C, COX2.926 G > C, and COX2.3050 G > C) were genotyped using fluorescent hybridization probes among 131 patients with sarcoidosis (63 males; mean age: 47 +/- 15 years) and 157 healthy controls (83 males; mean age: 50 +/- 16 years). We employed a binomial multiple logistic regression analysis to test the association between the selected SNPs and disease susceptibility. The clinical, functional and radiological prognosis of the sarcoidosis patients was determined after a mean follow-up of 37.4 +/- 30.4 months. RESULTS Carriers of the homozygous CC genotype of the COX2.8473 T > C polymorphism had a higher risk of sarcoidosis compared with TT carriers (OR: 3.08; 95% CI: 1.2-7.7; p = 0.035). 84% of patients achieved improvement or complete remission at follow-up. No association between the investigated SNPs and prognosis was seen. CONCLUSIONS Our data suggest that the homozygous CC genotype of the COX2.8473 T > C polymorphism may be associated with sarcoidosis susceptibility. No significant association with prognosis was detected.
Collapse
|
33
|
Montes-Worboys A, Romero A, Casas AM, Arellano E, Juan JM, Moreno JA, Rodriguez Panadero F. Gene polimorphisms and biological factors as possible predictors for patients with pleural metastatic breast cancer. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.10671] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
10671 Background: Pronosis of breast cancer varies widely in patients with similar clinical features. Therefore, we investigated other factors with possible prognostic value. The CYP17 gene has a polimorphism related to a increased susceptibility to breast cancer (single T; A1 allele to C; A2 allele). ( Mitrunen et al. Cancer Epidemiol Biomarkers Prev 2000,9;12;1343–8). On the other hand, it has been found in the MTHFR gene a common C-T substitution at nucleotide 677 that is associated with reduced enzyme activity and increased risk of breast cancer (Capmbell et al., Breast Cancer Research 2002;4,6:R14). Other genes such as GSTT1 and GSTM1 variant genotypes have a controversial association to breast cancer. We have analyzed the genotype and biological factors in a group of patients with pleural metastatic cancer of the breast and compared it to a control group of women with no cancer. Methods: Forty-six patients with breast cancer and forty women as controls were includes in the study. Age at diagnosis of the primary tumor, TNM staging, interval free of disease, estrogen and progesteron receptors, Ki67, p53 and Her-2neu expression were recorded, as well as survival from the time of diagnosis and polimorphism of CYP17, MTHFR, GSTT1 and GSTM1 genes. Results: Mean survival differed significantly between patients having pleural effusion as the first site of relapse as compared to those with other sites of relapse (28’9 vs 11’9 months, p = 0’004). A high Ki67 expression correlated best with longer survival after talc pleurodesis. We detected a high frequency in the CYP17 A2 variant genotype in patients with metastatic breast cancer compared to the control group. As for MTFHR gene, we found a high frequency for the T/T genotypes variant in breast cancer group. No significant differences between control and cancer group were found in either GSTT1 and GSTM1 gene variations. Conclusions: Genotype and biological factors, such as factors investigated in this study, play an important role as predictors for patients with pleural metastatic breast cancer. No significant financial relationships to disclose.
Collapse
|